Skip to content
Clinical Trials – home
Therapeutic area

Musculoskeletal and connective tissue disorders – page 42

  • 872 clinical trials
  • 359 recruiting
  • 331 conditions
  • 28 countries

Conditions in this area

331 conditions with trials, the busiest first

Clinical trials in Musculoskeletal and connective tissue disorders

872 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

872 clinical trials

Rheumatoid arthritis

Not recruiting

Study on the Effects of IMVT-1402 for Adults with Difficult-to-Treat Rheumatoid Arthritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Obesity+2

Not recruiting

Study of Retatrutide for Patients with Obesity, Overweight, and Chronic Low Back Pain

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-77242113
  • Sponsor:Janssen Cilag International

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Osteoarthritis

Not recruiting

Study on the Effects of LNA043 for Patients with Knee Osteoarthritis

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:LNA043
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Not recruiting

Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:MoonLake Immunotherapeutics AG

Study on the Effects of AGA2118 for Postmenopausal Women with Osteoporosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AGA2118
  • Sponsor:Angitia Inc. Ltd.

Rheumatoid arthritis

Not recruiting

Study on the Effectiveness and Safety of CT-P13 for Patients with Moderate to Severe Rheumatoid Arthritis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Folic Acid
  • Sponsor:Celltrion Inc.

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriatic arthropathy

Not recruiting

Study on the Effects and Safety of Guselkumab for Patients with Active Psoriatic Arthritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Myasthenia gravis

Not recruiting

Study on Long-Term Safety and Effectiveness of Zilucoplan in Adults with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zilucoplan
  • Sponsor:UCB Biopharma

Osteoporosis

Not recruiting

Study Comparing MAB-22 and Denosumab for Treating Osteoporosis in Postmenopausal Women

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Denosumab
  • Sponsor:Xentria Inc.

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.